TSR-042 is the first TESARO immuno-oncology candidate to enter a registration program Ongoing clinical trial expanded to enroll patients with endometrial cancer Patient-centric administration schedule ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback